Search details
1.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Lancet
; 402(10409): 1272-1281, 2023 10 07.
Article
in English
| MEDLINE | ID: mdl-37708904
2.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Lancet
; 402(10408): 1133-1146, 2023 09 30.
Article
in English
| MEDLINE | ID: mdl-37499670
3.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 436, 2024 Apr 08.
Article
in English
| MEDLINE | ID: mdl-38589856
4.
Injectable Thermogelling Nanostructured Ink as Simultaneous Optical and Magnetic Resonance Imaging Contrast Agent for Image-Guided Surgery.
Biomacromolecules
; 2024 May 23.
Article
in English
| MEDLINE | ID: mdl-38783486
5.
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022.
Gastric Cancer
; 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38634954
6.
p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells.
J Biol Chem
; 298(9): 102353, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35944584
7.
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion.
Blood
; 135(23): 2071-2084, 2020 06 04.
Article
in English
| MEDLINE | ID: mdl-31990287
8.
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.
Medicina (Kaunas)
; 58(11)2022 Oct 27.
Article
in English
| MEDLINE | ID: mdl-36363500
9.
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
Pancreatology
; 2021 Apr 19.
Article
in English
| MEDLINE | ID: mdl-33896692
10.
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
Future Oncol
; 17(4): 389-402, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33034201
11.
Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer.
Future Oncol
; 17(15): 1843-1854, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33663227
12.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol
; 21(5): 671-684, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32203698
13.
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma.
Ann Surg Oncol
; 27(13): 5325-5334, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32388740
14.
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.
Future Oncol
; 16(30): 2385-2399, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32677452
15.
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 563, 2024 May 06.
Article
in English
| MEDLINE | ID: mdl-38711003
16.
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data.
HPB (Oxford)
; 21(5): 596-603, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30366881
17.
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Br J Cancer
; 119(10): 1208-1214, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30318515
18.
The curious case of Gαs gain-of-function in neoplasia.
BMC Cancer
; 18(1): 293, 2018 03 15.
Article
in English
| MEDLINE | ID: mdl-29544460
19.
Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results.
Pancreatology
; 18(4): 420-428, 2018 Jun.
Article
in English
| MEDLINE | ID: mdl-29709409
20.
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.
Drug Resist Updat
; 33-35: 36-42, 2017 11.
Article
in English
| MEDLINE | ID: mdl-29145973